Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DR 10624

Drug Profile

DR 10624

Alternative Names: DR-10624

Latest Information Update: 10 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang Doer Biologics
  • Class Antihyperglycaemics; Hepatoprotectants; Immunoglobulin Fc fragments; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Obesity
  • Phase I Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 05 Jul 2024 Zhejiang Doer Biologics completes enrolment in its phase-Ib/IIa clinical trials in Obesity in New Zealand (SC) (NCT05378893)
  • 01 Aug 2023 Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approves IND application for DR 10624 for Obesity in China
  • 17 Jul 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis in China (SC), prior to July 2023 (Zhejiang Doer Biologics pipeline, July 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top